The DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Open accessAbstract
PURPOSE: An ASCO provisional clinical opinion offers timely clinical direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This provisional clinical opinion addresses the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors. CLINICAL CONTEXT: An increasing number of therapies are approved to treat cancers harboring specific genomic biomarkers. However, there is a lack of clarity as to when tumor genomic sequencing should be ordered, what type of assays should be performed, and how to interpret the results for treatment selection. PROVISIONAL CLINICAL OPINION: Patients with metastatic or advanced cancer should undergo genomic sequencing in a certified laboratory if the presence of one or more specific genomic alterations has regulatory approval as biomarkers to guide the use of or exclusion from certain treatments for their disease. Multigene panel–based assays should be used if more than one biomarker-linked therapy is approved for the patient's disease. Site-agnostic approvals for any cancer with a high tumor mutation burden, mismatch repair deficiency, or neurotrophic tyrosine receptor kinase ( NTRK) fusions provide a rationale for genomic testing for all solid tumors. Multigene testing may also assist in treatment selection by identifying additional targets when there are few or no genotype-based therapy approvals for the patient's disease. For treatment planning, the clinician should consider the functional impact of the targeted alteration and expected efficacy of genomic biomarker–linked options relative to other approved or investigational treatments. Additional information is available at www.asco.org/assays-and-predictive-markers-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Studies have supported the concept of branched evolution, with variable ITH in different tumor types.(185,186) The presence of additional cancer drivers or specific coalterations may limit targeted therapy efficacy.”
BackgroundImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Self-citationTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201 · cited 1×
“Subsequent studies have defined a consensus list of cancer driver genes(11) and patterns of cooccurrence and mutual exclusivity of these alterations across different cancer types.(12) Numerous groups maintain knowledge bases(13) of actionable alterations and their associated therapeutic implications.”
BackgroundSelf-citationMicrosatellite Instability in Cancer of the Proximal Colon
Thibodeau, S. N., Bren, G., & Schaid, D. (1993) · Science · doi:10.1126/science.8484122 · Cited by 3,130
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Self-citationMarabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Hauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationClues to the Pathogenesis of Familial Colorectal Cancer
Aaltonen, L. A., Peltomäki, P., Leach, F. S., Sistonen, P., Pylkkänen, L., Mecklin, J.-P., Järvinen, H., Powell, S. M., Jen, J., Hamilton, S. R., et al. (1993) · Science · doi:10.1126/science.8484121 · Cited by 2,710
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
Self-citationTP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Self-citationCrizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · cited 1×
“Clinical trials that led to the FDA approval of crizotinib in ALK andROS1 fusion–positive patients reported a 65% and 72% ORR, respectively.(120,121) In addition to ALK and ROS1 fusions in NSCLC, RET targeted agents such as selpercatinib are FDA-approved(122) for RET fusion–positive lung and thyroid cancers.”
BackgroundAACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Self-citationIncidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., Markowitz, S., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887
Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
HGVS Recommendations for the Description of Sequence Variants: 2016 Update
den Dunnen, J. T., Dalgleish, R., Maglott, D. R., Hart, R. K., Greenblatt, M. S., McGowan-Jordan, J., Roux, A.-F., Smith, T., Antonarakis, S. E., Taschner, P. E. M., et al. (2016) · Human Mutation · doi:10.1002/humu.22981 · Cited by 1,653
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611
Self-citationBean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Mutations of two P/WS homologues in hereditary nonpolyposis colon cancer
Nicolaides, N. C., Papadopoulos, N., Liu, B., Weit, Y.-F., Carter, K. C., Ruben, S. M., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., Fraser, C. M., et al. (1994) · Nature · doi:10.1038/371075a0 · Cited by 1,545
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,309
Shitara, K., Özgüroğlu, M., Bang, Y.-J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., Fornaro, L., Olesiński, T., Caglevic, C., Chung, H. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31257-1 · Cited by 1,296
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Chung, H. C., Ros, W., Delord, J.-P., Perets, R., Italiano, A., Shapira-Frommer, R., Manzuk, L., Piha-Paul, S. A., Xu, L., Zeigenfuss, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01265 · Cited by 1,069
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Woodcock, J., & LaVange, L. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510062 · Cited by 1,020
Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005
Classification and characterization of microsatellite instability across 18 cancer types
Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016) · Nature Medicine · doi:10.1038/nm.4191 · Cited by 991
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965
Merker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8671 · Cited by 959
Self-citationAnalysis of mismatch repair genes in hereditary non–polyposis colorectal cancer patients
Liu, B., Parsons, R., Papadopoulos, N., Nicolaides, N. C., Lynch, H. T., Watson, P., Jass, J. R., Dunlop, M., Wyllie, A., Peltomäki, P., et al. (1996) · Nature Medicine · doi:10.1038/nm0296-169 · Cited by 945
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 912
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C., Knezevich, S. R., Huntsman, D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L., Carneiro, F., MacPherson, N., Horsman, D., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 911
Integrative clinical genomics of metastatic cancer
Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature · doi:10.1038/nature23306 · Cited by 863
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Sha, D., Jin, Z., Budczies, J., Kluck, K., Stenzinger, A., & Sinicrope, F. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0522 · Cited by 859
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Self-citationMateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., Gonzalez-Perez, A., Lopez-Bigas, N., Ng, C. K. Y., Bedard, P. L., Tortora, G., Douillard, J.-Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy263 · Cited by 815
Self-citationChang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808
PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C.-J., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 784
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775
Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci915 · Cited by 686
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674
Self-citationFirst FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
Lemery, S., Keegan, P., & Pazdur, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1709968 · Cited by 664
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Powles, T., Assaf, Z. J., Davarpanah, N., Banchereau, R., Szabados, B. E., Yuen, K. C., Grivas, P., Hussain, M., Oudard, S., Gschwend, J. E., et al. (2021) · Nature · doi:10.1038/s41586-021-03642-9 · Cited by 646
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Griffith, M., Spies, N. C., Krysiak, K., McMichael, J. F., Coffman, A. C., Danos, A. M., Ainscough, B. J., Ramirez, C. A., Rieke, D. T., Kujan, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3774 · Cited by 628
The emerging clinical relevance of genomics in cancer medicine
Berger, M. F., & Mardis, E. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0002-6 · Cited by 626
Patient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
Gao, Q., Liang, W.-W., Foltz, S. M., Mutharasu, G., Jayasinghe, R. G., Cao, S., Liao, W.-W., Reynolds, S. M., Wyczalkowski, M. A., Yao, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.050 · Cited by 604
Self-citationTumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., et al. (2017) · Nature · doi:10.1038/nature23291 · Cited by 562 · cited 1×
“Preclinical studies have culminated in classifying activating BRAF variants into three classes of mutations on the basis of their biochemical properties.(61)”
BackgroundGoyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G., Lennerz, J. K., Vu, P., Deshpande, V., Kambadakone, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1000 · Cited by 552
Van Allen, E. M., Wagle, N., Stojanov, P., Perrin, D. L., Cibulskis, K., Marlow, S., Jane-Valbuena, J., Friedrich, D. C., Kryukov, G., Carter, S. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3559 · Cited by 546
Self-citationNTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
Solomon, J. P., Linkov, I., Rosado, A., Mullaney, K., Rosen, E. Y., Frosina, D., Jungbluth, A. A., Zehir, A., Benayed, R., Drilon, A., et al. (2020) · Modern Pathology · doi:10.1038/s41379-019-0324-7 · Cited by 546
Subbiah, V., Lassen, U., Élez, E., Italiano, A., Curigliano, G., Javle, M., de Braud, F., Prager, G. W., Greil, R., Stein, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30321-1 · Cited by 533
Mandelker, D., Zhang, L., Kemel, Y., Stadler, Z. K., Joseph, V., Zehir, A., Pradhan, N., Arnold, A., Walsh, M. F., Li, Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.11137 · Cited by 511
Self-citationMerino, D. M., McShane, L. M., Fabrizio, D., Funari, V., Chen, S.-J., White, J. R., Wenz, P., Baden, J., Barrett, J. C., Chaudhary, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000147 · Cited by 507
Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Esteller, M., Levine, R., Baylin, S. B., Ellenson, L. H., & Herman, J. G. (1998) · Oncogene · doi:10.1038/sj.onc.1202178 · Cited by 493
Molecular characterization of cancers with NTRK gene fusions
Gatalica, Z., Xiu, J., Swensen, J., & Vranic, S. (2019) · Modern Pathology · doi:10.1038/s41379-018-0118-3 · Cited by 486
Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines
Roy, S., Coldren, C., Karunamurthy, A., Kip, N. S., Klee, E. W., Lincoln, S. E., Leon, A., Pullambhatla, M., Temple-Smolkin, R. L., Voelkerding, K. V., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.11.003 · Cited by 469
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Hechtman, J. F., Benayed, R., Hyman, D. M., Drilon, A., Zehir, A., Frosina, D., Arcila, M. E., Dogan, S., Klimstra, D. S., Ladanyi, M., et al. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000911 · Cited by 468
Vanderwalde, A., Spetzler, D., Xiao, N., Gatalica, Z., & Marshall, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1372 · Cited by 458
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Lord, C. J., & Ashworth, A. (2013) · Nature Medicine · doi:10.1038/nm.3369 · Cited by 449
Drilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0507 · Cited by 439
Evidence for a 15; 17 translocation in every patient with acute promyelocytic leukemia
Larson, R. A., Kondo, K., Vardiman, J. W., Butler, A. E., Golomb, H. M., & Rowley, J. D. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90994-x · Cited by 417
Accelerating Discovery of Functional Mutant Alleles in Cancer
Chang, M. T., Bhattarai, T. S., Schram, A. M., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., Chakravarty, D., Phillips, S., Kandoth, C., Penson, A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0321 · Cited by 409
Self-citationCharacterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
Schrock, A. B., Frampton, G. M., Suh, J., Chalmers, Z. R., Rosenzweig, M., Erlich, R. L., Halmos, B., Goldman, J., Forde, P., Leuenberger, K., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.004 · Cited by 384
The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes
Kim, T.-M., Laird, P. W., & Park, P. J. (2013) · Cell · doi:10.1016/j.cell.2013.10.015 · Cited by 380
Goyal, L., Shi, L., Liu, L. Y., Fece de la Cruz, F., Lennerz, J. K., Raghavan, S., Leschiner, I., Elagina, L., Siravegna, G., Ng, R. W. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0182 · Cited by 376
Racial/ethnic disparities in genomic sequencing
Spratt, D. E., Chan, T., Waldron, L., Speers, C., Feng, F. Y., Ogunwobi, O. O., & Osborne, J. R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1854 · Cited by 375
Chornokur, G., Dalton, K., Borysova, M. E., & Kumar, N. B. (2011) · The Prostate · doi:10.1002/pros.21314 · Cited by 343
Swetter, S. M., Thompson, J. A., Albertini, M. R., Barker, C. A., Baumgartner, J., Boland, G., Chmielowski, B., DiMaio, D., Durham, A., Fields, R. C., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0018 · Cited by 340
Patel, M. I., Lopez, A. M., Blackstock, W., Reeder-Hayes, K., Moushey, E. A., Phillips, J., & Tap, W. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00642 · Cited by 338
Plimack, E. R., Bellmunt, J., Gupta, S., Berger, R., Chow, L. Q. M., Juco, J., Lunceford, J., Saraf, S., Perini, R. F., & O'Donnell, P. H. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30007-4 · Cited by 335
Mittendorf, E. A., Wu, Y., Scaltriti, M., Meric-Bernstam, F., Hunt, K. K., Dawood, S., Esteva, F. J., Buzdar, A. U., Chen, H., Eksambi, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1735 · Cited by 330
Self-citationWatkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327
Malkhosyan, S., Rampino, N., Yamamoto, H., & Perucho, M. (1996) · Nature · doi:10.1038/382499a0 · Cited by 327
Radovich, M., Jiang, G., Hancock, B. A., Chitambar, C., Nanda, R., Falkson, C., Lynce, F. C., Gallagher, C., Isaacs, C., Blaya, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2295 · Cited by 307
Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review
Newman, L. A., & Kaljee, L. M. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.0005 · Cited by 304
Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D., Hamilton, S. R., Williams, P. M., Iafrate, A. J., Sklar, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03010 · Cited by 294
Self-citationTwo Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Katayama, R., Friboulet, L., Koike, S., Lockerman, E. L., Khan, T. M., Gainor, J. F., Iafrate, A. J., Takeuchi, K., Taiji, M., Okuno, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1511 · Cited by 290
Solomon, B. J., Tan, L., Lin, J. J., Wong, S. Q., Hollizeck, S., Ebata, K., Tuch, B. B., Yoda, S., Gainor, J. F., Sequist, L. V., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.006 · Cited by 289
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
Redig, A. J., & Jänne, P. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.8433 · Cited by 278
Identifying patients with NTRK fusion cancer
Solomon, J. P., Benayed, R., Hechtman, J. F., & Ladanyi, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz384 · Cited by 270
Fabrizio, D. A., George Jr, T. J., Dunne, R. F., Frampton, G., Sun, J., Gowen, K., Kennedy, M., Greenbowe, J., Schrock, A. B., Hezel, A. F., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.05.06 · Cited by 260
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
Ross, J. S., Wang, K., Gay, L., Otto, G. A., White, E., Iwanik, K., Palmer, G., Yelensky, R., Lipson, D. M., Chmielecki, J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.216 · Cited by 244
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
Beaubier, N., Tell, R., Lau, D., Parsons, J. R., Bush, S., Perera, J., Sorrells, S., Baker, T., Chang, A., Michuda, J., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26797 · Cited by 244
Raja, R., Kuziora, M., Brohawn, P. Z., Higgs, B. W., Gupta, A., Dennis, P. A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0386 · Cited by 239
Hsiao, S. J., Zehir, A., Sireci, A. N., & Aisner, D. L. (2019) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.03.008 · Cited by 226
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 226
Self-citationGuidance for laboratories performing molecular pathology for cancer patients
Cree, I. A., Deans, Z., Ligtenberg, M. J. L., Normanno, N., Edsjö, A., Rouleau, E., Solé, F., Thunnissen, E., Timens, W., Schuuring, E., et al. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202404 · Cited by 214
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin, H.-T., Choi, Y.-L., Yun, J. W., Kim, N. K. D., Kim, S.-Y., Jeon, H. J., Nam, J.-Y., Lee, C., Ryu, D., Kim, S. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01470-y · Cited by 203
A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
Meric-Bernstam, F., Johnson, A., Holla, V., Bailey, A. M., Brusco, L., Chen, K., Routbort, M., Patel, K. P., Zeng, J., Kopetz, S., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv098 · Cited by 199
Self-citationMeric-Bernstam, F., Brusco, L., Daniels, M., Wathoo, C., Bailey, A. M., Strong, L., Shaw, K., Lu, K., Qi, Y., Zhao, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw018 · Cited by 195
Self-citationChimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite
Grünewald, T. G. P., Bernard, V., Gilardi-Hebenstreit, P., Raynal, V., Surdez, D., Aynaud, M.-M., Mirabeau, O., Cidre-Aranaz, F., Tirode, F., Zaidi, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3363 · Cited by 186
Irvin, W. J., Walko, C. M., Weck, K. E., Ibrahim, J. G., Chiu, W. K., Dees, E. C., Moore, S. G., Olajide, O. A., Graham, M. L., Canale, S. T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4427 · Cited by 181
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
Stadler, Z. K., Maio, A., Chakravarty, D., Kemel, Y. M., Sheehan, M. R., Salo‐Mullen, E. E., Tkachuk, K. A., Fong, C. J., Nguyen, B., Erakky, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03661 · Cited by 175
Self-citationRose Brannon, A., Jayakumaran, G., Diosdado, M., Patel, J., Razumova, A., Hu, Y., Meng, F., Haque, M., Sadowska, J., Murphy, B. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24109-5 · Cited by 174
Bradford, D., Larkins, E., Mushti, S. L., Rodriguez, L., Skinner, A. M., Helms, W. S., Price, L. S. L., Zirkelbach, J. F., Li, Y., Liu, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3558 · Cited by 171
Rosen, E. Y., Goldman, D. A., Hechtman, J. F., Benayed, R., Schram, A. M., Cocco, E., Shifman, S. G., Gong, Y., Kundra, R., Solomon, J. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3165 · Cited by 168
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
Variant Interpretation for Cancer Consortium, Wagner, A. H., Walsh, B., Mayfield, G., Tamborero, D., Sonkin, D., Krysiak, K., Deu-Pons, J., Duren, R. P., Gao, J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0603-8 · Cited by 164
Self-citationSalem, M. E., Bodor, J. N., Puccini, A., Xiu, J., Goldberg, R. M., Grothey, A., Korn, W. M., Shields, A. F., Worrilow, W. M., Kim, E. S., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33115 · Cited by 164
Cocco, E., Benhamida, J., Middha, S., Zehir, A., Mullaney, K., Shia, J., Yaeger, R., Zhang, L., Wong, D., Villafania, L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3126 · Cited by 163
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Dagogo‐Jack, I., Rooney, M. M., Lin, J. J., Nagy, R. J., Yeap, B. Y., Hubbeling, H., Chin, E. N., Ackil, J., Farago, A. F., Hata, A. N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1436 · Cited by 160
Patterson, S. E., Liu, R., Statz, C. M., Durkin, D., Lakshminarayana, A., & Mockus, S. M. (2016) · Human Genomics · doi:10.1186/s40246-016-0061-7 · Cited by 157
Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
McLeod, H. L. (2013) · Science · doi:10.1126/science.1234139 · Cited by 156
Katayama, R., Gong, B., Togashi, N., Miyamoto, M., Kiga, M., Iwasaki, S., Kamai, Y., Tominaga, Y., Takeda, Y., Kagoshima, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11496-z · Cited by 151
Schrock, A. B., Zhu, V. W., Hsieh, W.-S., Madison, R. W., Creelan, B., Silberberg, J., Costin, D., Bharne, A., Bonta, I. R., Bosemani, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.027 · Cited by 150
Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
Menzer, C., Menzies, A. M., Carlino, M. S., Reijers, I. L. M., Groen, E. J., Eigentler, T., de Groot, J. W. B., van der Veldt, A. A. M., Johnson, D. B., Meiß, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00489 · Cited by 145
Parikh, A. R., Mojtahed, A., Schneider, J. L., Kanter, K. N., Seventer, E. E. V., Fetter, I. J., Thabet, A., Fish, M. G., Teshome, B., Fosbenner, K. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3467 · Cited by 142
Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer
Lincoln, S. E., Nussbaum, R. L., Kurian, A. W., Nielsen, S. M., Das, K., Michalski, S. T., Yang, S., Ngo, N., Blanco, A. M., & Esplin, E. D. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.19452 · Cited by 139
Reardon, D. A., Kim, T. M., Frenel, J., Simonelli, M., Lopez, J. S., Subramaniam, D. S., Siu, L. L., Wang, H., Krishnan, S., Stein, K. F., et al. (2021) · Cancer · doi:10.1002/cncr.33378 · Cited by 136
van Belzen, I. A. E. M., Schönhuth, A., Kemmeren, P., & Hehir‐Kwa, J. Y. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00155-6 · Cited by 133
Belli, C., Penault-Llorca, F. M., Ladanyi, M., Normanno, N., Scoazec, J., Lacroix, L., Reis-Filho, J. S., Subbiah, V., Gainor, J. F., Endris, V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.021 · Cited by 130
Self-citationEndris, V., Buchhalter, I., Allgäuer, M., Rempel, E., Lier, A., Volckmar, A., Kirchner, M., von Winterfeld, M., Leichsenring, J., Neumann, O., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32002 · Cited by 128
Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer
Baudrin, L. G., Deleuze, J., & How‐Kit, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00621 · Cited by 121
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
Varghese, A. M., Arora, A., Capanu, M., Camacho, N., Won, H. H., Zehir, A., Gao, J., Chakravarty, D., Schultz, N. D., Klimstra, D. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx545 · Cited by 117
Self-citationHuang, L., Fernandes, H., Zia, H. M., Tavassoli, P., Rennert, H., Pisapia, D. J., Imielinski, M. B., Sboner, A., Rubin, M. A., Kluk, M., et al. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw148 · Cited by 116
Hayashi, H., Takiguchi, Y., Minami, H., Akiyoshi, K., Segawa, Y., Ueda, H., Iwamoto, Y., Kondoh, C. N., Matsumoto, K., Takahashi, S. I., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4643 · Cited by 113
A machine learning approach for somatic mutation discovery
Wood, D. E., White, J. R., Georgiadis, A. P., Emburgh, B. V., Parpart-Li, S. T., Mitchell, J., Anagnostou, V., Niknafs, N., Karchin, R., Papp, E., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7939 · Cited by 110
Hanker, A. B., Brewer, M. R., Sheehan, J. H., Koch, J. P., Sliwoski, G. R., Nagy, R. J., Lanman, R. B., Berger, M. F., Hyman, D. M., Solit, D. B., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1431 · Cited by 109
Self-citationBarone, A. K., Hazarika, M., Theoret, M. R., Mishra-Kalyani, P. S., Chen, H., He, K., Sridhara, R., Subramaniam, S., Fletcher, E. P., Wang, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0664 · Cited by 90
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology
Tao, J. J., Schram, A. M., & Hyman, D. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062016-050343 · Cited by 89
New paradigms in clonal evolution: punctuated equilibrium in cancer
Cross, W. C. H., Graham, T. A., & Wright, N. A. (2016) · The Journal of Pathology · doi:10.1002/path.4757 · Cited by 88
Pairawan, S. S., Hess, K. R., Jankú, F., Sánchez, N., Shaw, K. R. M., Eng, C., Damodaran, S., Javle, M. M., Kaseb, A. O., Hong, D. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0306 · Cited by 87
Self-citationTamoxifen and CYP2D6: A Contradiction of Data
Hertz, D. L., McLeod, H. L., & Irvin, W. J. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0418 · Cited by 86
The Impact of Race and Comorbidity on Survival in Endometrial Cancer
Olson, S. H., Atoria, C. L., Coté, M. L., Cook, L. S., Rastogi, R. M., Soslow, R. A., Brown, C. L., & Elkin, E. B. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0735 · Cited by 82
Vaclová, T., Grazini, U., Ward, L. S. C., O’Neill, D. J., Markovets, A. A., Huang, X., Chmielecki, J., Hartmaier, R. J., Thress, K. S., Smith, P. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22057-8 · Cited by 78
Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
van de Haar, J., Hoes, L. R., Roepman, P., Lolkema, M. P., Verheul, H. M. W., Gelderblom, H. A. J., Langen, A. J. D., Smit, E. F., Cuppen, E. P. J. G., Wessels, L. F. A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01448-w · Cited by 74
Wang, J., Yi, Y., Xiao, Y., Lin, D., Liang, L., Teng, L., Ying, J. M., Lu, T., Liu, Y., Guan, Y., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0212-1 · Cited by 58
Hodroj, K., Barthélémy, D., Lega, J., Grenet, G., Gagnieu, M., Walter, T., Guitton, J., & Payen, L. F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100125 · Cited by 57
Suda, K., & Mitsudomi, T. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-186 · Cited by 48
Baghdadi, T. A., Garrett-Mayer, E. S., Halabi, S., Mangat, P. K., Rich, P., Ahn, E. R., Chai, S., Rygiel, A. L., Osayameh, O., Antonelli, K. R., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00752-8 · Cited by 46
“Personalized Cancer Therapy”: A Publicly Available Precision Oncology Resource
Kurnit, K. C., Bailey, A. M., Zeng, J., Johnson, A. M., Shufean, M. A., Brusco, L., Litzenburger, B. C., Sánchez, N., Khotskaya, Y. B., Holla, V. R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0341 · Cited by 45
Self-citationDagogo‐Jack, I., Piotrowska, Z., Cobb, R. G., Banwait, M. K., Lennerz, J. K., Hata, A. N., Digumarthy, S. R., & Sequist, L. V. D. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.046 · Cited by 43
Niu, D., Li, L., Yu, Y., Zang, W., Li, Z., Zhou, L., Jia, L., Rao, G., Gao, L., Cheng, G., et al. (2020) · Pathology & Oncology Research · doi:10.1007/s12253-020-00844-w · Cited by 43
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults
Bebb, D. G., Banerji, S. O., Blais, N., Desmeules, P., Gill, S., Grin, A., Feilotter, H. E., Hansen, A. R., Hyrcza, M. D., Krzyzanowska, M. K., et al. (2021) · Current Oncology · doi:10.3390/curroncol28010053 · Cited by 43
Radonic, T., Geurts-Giele, W. R. R., Samsom, K. G., Roemen, G. M. J. M., von der Thüsen, J. H., Thunnissen, E., Meijssen, I. C., Sleddens, H. F. B. M., Dinjens, W. N. M., Boelens, M. C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1619 · Cited by 43
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Akçakanat, A., Zheng, X., Pico, C. X. C., Kim, T., Chen, K., Korkut, A., Şahin, A. A., Holla, V. R., Tarco, E., Singh, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4048 · Cited by 39
Self-citationNugent, A., Conatser, K. R., Turner, L. L., Nugent, J. T., Sarino, E. M., & Ricks‐Santi, L. J. (2019) · Genetics in Medicine · doi:10.1038/s41436-019-0558-2 · Cited by 38
Cleary, J. M., Wang, V., Heist, R. S., Kopetz, S., Mitchell, E. P., Zwiebel, J. A., Kapner, K. S., Chen, H. X., Li, S., Gray, R. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0066 · Cited by 38
Self-citationMerker, J. D., Devereaux, K. A., Iafrate, A. J., Kamel‐Reid, S., Kim, A. S., Moncur, J. T., Montgomery, S. B., Nagarajan, R., Portier, B. P., Routbort, M. J., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0336-cp · Cited by 35
Self-citationStandard operating procedure for curation and clinical interpretation of variants in cancer
Danos, A. M., Krysiak, K., Barnell, E. K., Coffman, A. C., McMichael, J. F., Kiwala, S., Spies, N. C., Sheta, L. M., Pema, S. P., Kujan, L., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0687-x · Cited by 30
Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
Strohmeier, S., Brčić, I., Popper, H., Liegl‐Atzwanger, B., Lindenmann, J., & Brčić, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-89373-3 · Cited by 25
Beau‐Faller, M., Pencreach, E., Leduc, C., Blons, H., Merlio, J., Bringuier, P., de Fraipont, F., Escande, F., Lemoine, A., Ouafik, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.013 · Cited by 23
‘Overcoming the Bottleneck’: Knowledge Architectures for Genomic Data Interpretation in Oncology
Cambrosio, A., Campbell, J., Vignola‐Gagné, É., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-37177-7_16 · Cited by 22
Rodríguez-Moreno, J. F., Apellániz-Ruiz, M., Roldán‐Romero, J. M., Durán, I., Beltrán, L., Montero‐Conde, C., Cascón, A., Robledo, M., García-Donás, J., & Rodríguez‐Antona, C. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7018 · Cited by 21
Moncur, J. T., Bartley, A. N., Bridge, J. A., Kamel‐Reid, S., Lazar, A. J., Lindeman, N. I., Long, T. A., Merker, J. D., Rai, A. J., Rimm, D. L., et al. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0396-cp · Cited by 16
Self-citationWang, Y., He, Y., Tian, P., Wang, W., Wang, K., Chuai, S., Li, Y., Zhao, S., Wang, Y., & Li, W. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-915 · Cited by 14
Parilla, M., & Ritterhouse, L. L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00370 · Cited by 12
Cited by
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Suehnholz, S. P., Nissan, M. H., Zhang, H., Kundra, R., Nandakumar, S., Lu, C., Carrero, S., Dhaneshwar, A., Fernandez, N., Xu, B. W., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0467 · Cited by 401
Self-citationClinVar: updates to support classifications of both germline and somatic variants
Landrum, M. J., Chitipiralla, S., Kaur, K., Brown, G., Chen, C., Hart, J., Hoffman, D., Jang, W., Liu, C., Maddipatla, Z., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae1090 · Cited by 182
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline
Yu, E. Y., Rumble, R. B., Agarwal, N., Cheng, H. H., Eggener, S. E., Bitting, R. L., Beltran, H., Giri, V. N., Spratt, D., Mahal, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02608 · Cited by 64
Metadata
- Authors
- Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., Lieu, C., André, F., Azad, N., Borad, M., Tafe, L., Messersmith, H., Robson, M., & Meric-Bernstam, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-04-10
- Volume
- 40
- Issue
- 11
- Pages
- 1231-1258
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4213091130
- Cited by
- 266
- References
- 186
- FWCI
- 17.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.